Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

November 22, 2019

Study Completion Date

October 30, 2020

Conditions
Chronic Viral Hepatitis B With Delta-agent
Interventions
DRUG

Myrcludex B

Lyophilised powder for solution for subcutaneous injection

DRUG

PEG IFN alfa-2a

solution for subcutaneous injection, once per week

DRUG

Tenofovir

Film-coated tablets, 300 mg, per os, once daily

Trial Locations (7)

129110

Moscow Regional Research and Clinical Institute, Moscow

Unknown

"State Budgetary educational institution of higher professional education South Ural State Medical University Ministry of healthcare", Chelyabinsk

"State Budgetary Institution of healthcare Specialized Clinical Infectious Diseases Hospital Ministry of Health", Krasnodar

"Federal Budget Institution of Science Central Research Institute of Epidemiology of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance", Moscow

"LLC Clinic of Modern Medicine", Moscow

"Medical Company Gepatolog LLC", Samara

State Budgetary Institution of healthcare 'Stavropol regional clinical hospital', Stavropol

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Hepatera Ltd.

INDUSTRY

NCT02888106 - Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent | Biotech Hunter | Biotech Hunter